Drug profile

The FDA adverse-event record for Hydromorphone Hcl Injectable

109 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Hydromorphone Hcl Injectable. See the species affected, top reactions, and outcomes below.

109
adverse-event reports
21.1%
death-coded share
Dog
most-reported species
14
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
109
Total Reports
23
Deaths Reported
21.1%
Death Rate

Active Ingredients

Hydromorphone Hcl Injectable

Administration Routes

UnknownIntramuscularIntravenousSubcutaneous

Species Affected

Dog 101
Cat 6
Rabbit 2

Most Affected Breeds

Retriever - Labrador 10
Dog (unknown) 8
Chihuahua 8
Crossbred Canine/dog 5
Shepherd (unspecified) 4
Boxer (German Boxer) 4
Shepherd Dog - German 4
Domestic Shorthair 4
Terrier - Bull - American Pit 3
Bulldog - American 3

Most Reported Reactions

Vomiting 14
Death 14
Bradycardia 13
Lack of efficacy - NOS 13
Cardiac arrest 12
Lethargy (see also Central nervous system depression in 'Neurological') 10
Death by euthanasia 8
Anaphylaxis 8
Seizure NOS 7
Elevated total bilirubin 6
Heart block NOS 6
Panting 6

Outcome Breakdown

Recovered/Normal
43 (39.4%)
Ongoing
40 (36.7%)
Died
15 (13.8%)
Euthanized
8 (7.3%)
Outcome Unknown
3 (2.8%)

Hydromorphone Hcl Injectable Adverse Event Insights

109 reports name Hydromorphone Hcl Injectable; 23 recorded a death outcome (21.1% of reported events, not a population-level mortality rate). Active ingredient: Hydromorphone Hcl Injectable. Administration routes: Unknown, Intramuscular, Intravenous, Subcutaneous.

By species: Dog (101 reports), Cat (6 reports), Rabbit (2 reports). By breed: Retriever - Labrador (10), Dog (unknown) (8), Chihuahua (8).

Leading clinical signs: Vomiting (14), Death (14), Bradycardia (13), Lack of efficacy - NOS (13). Outcome, 109 coded reports: Recovered/Normal leads at 39.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.